Keywords: Progenics, Wyeth, Relistor, Licensing, Opioid induced constipation

Progenics regains global rights to Relistor from Wyeth; will seek new partners

Article | 15 October 2009

USA-based Progenics Pharmaceuticals says it is regaining all worldwide rights to the Relistor (methylnaltrexone) franchise from drug major Wyeth (which is in the process of being acquired by Pfizer in a $68 billion deal). Progenics licensed the drug to Wyeth Pharmaceuticals in 2005.

Progenics said it will assume full control of future development and commercialisation of subcutaneous Relistor after a one-year transition, and will immediately take over development of the oral form of the drug, as well as looking for a new partner .Relistor generated $3.2 million in sales in the second quarter of 2009, and analysts from Cowen & Co forecast annual revenue for the drug could reach $90 million by 2012. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in